Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.

PubWeight™: 0.90‹?›

🔗 View Article (PMID 16210086)

Published in Semin Oncol on October 01, 2005

Authors

Anthony J Murgo1

Author Affiliations

1: Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Bethesda, MD 20852, USA. murgoa@mail.nih.gov